Immune Monitoring Core

免疫监测核心

• 批准号: 7283554
• 负责人: JOHN D ALTMAN
• 金额: $ 33.4万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7283554
• 关键词: AIDS therapy; AIDS vaccines; Macaca mulatta; antigen presentation; biomedical facility; enzyme linked immunosorbent assay; flow cytometry; human subject; immune response; neutralizing antibody; serology /serodiagnosis; vaccine evaluation; vaccinia virus; vector vaccine; viral vaccines; virus antigen; virus load

CORE C DESCRIPTION: Induction of HIV-specific immune responses is both a primary endpoint in the preclinical studies and a secondary endpoint in the clinical trial of novel MVA-based vaccines described in this IPCAVD application. Core C, the Immune Monitoring Core (IMC) of this application will perform state-of-the-art assays of both humoral and cellular immune responses for Projects 1 and 2 which describe preclinical experiments in rhesus macaques designed to determine the best MVA-based vectors to carry forward into a human clinical trial. The IMC will also perform these assays for the human clinical trial described in Core B. The Specific Aims of the IMC are: (1) to evaluate T cell immune responses to the HIV vaccine antigens, using validated Intracellular Cytokine Staining (ICS), ELISpot, and flow cytometry-based proliferation assays; (2) to test serum samples from vaccinated subjects for both HIV-binding and -neutralizing antibodies.

核心 C 描述：HIV 特异性免疫反应的诱导是主要终点 本 IPCAVD 申请中描述的基于 MVA 的新型疫苗的临床前研究和临床试验的次要终点。核心 C，该应用程序的免疫监测核心 (IMC) 将为项目 1 和 2 进行最先进的体液和细胞免疫反应测定，这些测定描述了恒河猴的临床前实验，旨在确定最佳的基于 MVA 的方法载体进行人体临床试验。 IMC 还将针对核心 B 中描述的人体临床试验进行这些测定。 IMC 的具体目标是：(1) 使用经过验证的细胞内细胞因子染色 (ICS)、ELISpot 评估 T 细胞对 HIV 疫苗抗原的免疫反应和基于流式细胞术的增殖测定； (2) 检测已接种疫苗受试者的血清样本中的 HIV 结合抗体和中和抗体。